Pacific Biosciences of California Inc
NASDAQ:PACB
Pacific Biosciences of California Inc
NASDAQ:PACB
Price:
1.27
USD
-5.93%
Market Closed
Market Cap:
$383.4m
Relative Value
The Relative Value of one
PACB
stock under the Base Case scenario is
2.81
USD.
Compared to the current market price of 1.27 USD,
Pacific Biosciences of California Inc
is
Undervalued by 55%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PACB
Relative Value
Base Case
2.81
USD
Undervaluation 55%
Multiples Across Competitors
PACB Competitors Multiples
Pacific Biosciences of California Inc Competitors
Pacific Biosciences of California Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Pacific Biosciences of California Inc
NASDAQ:PACB
|
383.5m USD | 2.4 | -0.7 | 2.5 | -3.2 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
990.7B USD | 346.9 | 4 107.3 | 1 176.9 | 2 266.3 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
179B USD | 4 | 26.7 | 18.8 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
131.7B USD | 5.4 | 36.4 | 18.6 | 27 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | 30.1 | 39.4 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.6B CHF | 5.2 | 35.5 | 26.5 | 26.5 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
262.9B CNY | 5.9 | 17.4 | 17.4 | 17.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.6B USD | 4.5 | 24.5 | 19.3 | 23 | |
| US |
|
Waters Corp
NYSE:WAT
|
27.8B USD | 8.8 | 43.2 | 27.9 | 35.1 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.6B USD | 1.7 | 20.4 | 11.5 | 17.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.8B USD | 5.9 | 27.4 | 20.4 | 22.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
